BioNTech实验性乳腺癌药物在试验中取得成功

动脉网2025-09-05

BioNTech与映恩生物合作研发的实验性乳腺癌药物在研究中取得成功，这是双方合作的首个成果。中期分析显示，该药物在治疗乳腺癌方面优于罗氏控股的老牌药物Kadcyla，使用新药的患者病情恶化或死亡风险更低。该试验在中国进行，针对228名癌症已扩散或不适合手术且曾接受过化疗和曲妥珠单抗治疗的患者。此次成功是BioNTech与映恩生物合作开展的首个后期试验成果，也是BioNTech抗癌化合物首次在可能...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2565597574?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-05 18:42","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2565597574","market":"us","top_or_hot":-1,"title":"BioNTech实验性乳腺癌药物在试验中取得成功","media":"动脉网","content":"<div>\n<p>BioNTech与映恩生物合作研发的实验性乳腺癌药物在研究中取得成功，这是双方合作的首个成果。中期分析显示，该药物在治疗乳腺癌方面优于罗氏控股的老牌药物Kadcyla，使用新药的患者病情恶化或死亡风险更低。该试验在中国进行，针对228名癌症已扩散或不适合手术且曾接受过化疗和曲妥珠单抗治疗的患者。此次成功是BioNTech与映恩生物合作开展的首个后期试验成果，也是BioNTech抗癌化合物首次在可能...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509051855019515b1e3&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech实验性乳腺癌药物在试验中取得成功</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech实验性乳腺癌药物在试验中取得成功\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-05 18:42 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509051855019515b1e3&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech与映恩生物合作研发的实验性乳腺癌药物在研究中取得成功，这是双方合作的首个成果。中期分析显示，该药物在治疗乳腺癌方面优于罗氏控股的老牌药物Kadcyla，使用新药的患者病情恶化或死亡风险更低。该试验在中国进行，针对228名癌症已扩散或不适合手术且曾接受过化疗和曲妥珠单抗治疗的患者。此次成功是BioNTech与映恩生物合作开展的首个后期试验成果，也是BioNTech抗癌化合物首次在可能...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509051855019515b1e3&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0640798160.USD","symbol_name":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509051855019515b1e3&s=b","article_id":"2565597574","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509051855019515b1e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2565597574","pubTimestamp":1757068920,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"BioNTech与映恩生物合作研发的实验性乳腺癌药物在研究中取得成功，这是双方合作的首个成果。中期分析显示，该药物在治疗乳腺癌方面优于罗氏控股的老牌药物Kadcyla，使用新药的患者病情恶化或死亡风险更低。该试验在中国进行，针对228名癌症已扩散或不适合手术且曾接受过化疗和曲妥珠单抗治疗的患者。此次成功是BioNTech与映恩生物合作开展的首个后期试验成果，也是BioNTech抗癌化合物首次在可能获监管批准的研究中成功。映恩生物专注研发癌症抗体偶联药物，与多家公司有合作，其海外交易引发投资者兴趣，股价自上市以来已上涨超280%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","LU1115378108.SGD":"Eastspring Investments - Global Emerging Markets Dynamic AS SGD","BK4006":"钢铁","TX":"特尔尼翁钢铁"},"translate_title":"BioNTech's experimental breast cancer drug succeeds in trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TX":0.9},"content_text":"BioNTech与映恩生物合作研发的实验性乳腺癌药物在研究中取得成功，这是双方合作的首个成果。中期分析显示，该药物在治疗乳腺癌方面优于罗氏控股的老牌药物Kadcyla，使用新药的患者病情恶化或死亡风险更低。该试验在中国进行，针对228名癌症已扩散或不适合手术且曾接受过化疗和曲妥珠单抗治疗的患者。此次成功是BioNTech与映恩生物合作开展的首个后期试验成果，也是BioNTech抗癌化合物首次在可能获监管批准的研究中成功。映恩生物专注研发癌症抗体偶联药物，与多家公司有合作，其海外交易引发投资者兴趣，股价自上市以来已上涨超280%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2565597574","isCrawlerRequest":true}